Posted on 12/06/2009 in Pharmaceutical Company Restructures Actelion is increasing its focus on its scientific and drug development, it has stated.
The current head of clinical development Isaac Kobrin will move into the newly created position of chief medical officer as of July 1st.
Guy Braunstein is to take his present position as a result.
The latter brings to the company over 20 years of experience and his most recent role has been chief medical officer at Merck Serono.
Managing director and chief executive officer of Actelion Jean-Paul Clozel remarked on how the partnership between the two employees will work.
"The sharing of this know-how ? will ensure continued rapid advancement of our innovative compounds that will make a real difference to patients," he stated.
Mr Clozel explained it would be their experiences of drug discovery, clinical development, registration and commercialisation that would allow them to achieve this.
In March, Actelion's board of directors proposed three new members to join the team. It was also announced one of the business' founding members Andre J Mueller would be retiring.Other news stories from 12/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
